What is BioBDx?
BioBehavioral Diagnostics Company (BioBDx) is a privately held entity focused on the development, manufacturing, and marketing of advanced diagnostic systems. Its primary objective is to provide quantitative assessment tools for behavioral disorders. The company's flagship product, the McLean Motion and Attention Test for Attention Deficit Hyperactivity Disorder (MMAT/ADHD System), is engineered to assist clinicians in making precise, office-based diagnoses for ADHD, thereby facilitating timely and appropriate treatment interventions.
How much funding has BioBDx raised?
BioBDx has raised a total of $22.3M across 4 funding rounds:
Series A
$8.5M
Series B
$10M
Debt
$700K
Debt
$3.1M
Series A (2007): $8.5M with participation from Tullis-Dickerson & Co. and Sevin Rosen Funds' companies
Series B (2010): $10M led by Sevin Rosen Funds and Tullis Health Investors
Debt (2011): $700K, investors not publicly disclosed
Debt (2011): $3.1M, investors not publicly disclosed
Key Investors in BioBDx
Sevin Rosen Funds
Sevin Rosen Funds is a venture capital firm with a history of investing in technology companies, particularly in the early stages of development. Their involvement suggests a belief in BioBDx's innovative technology and market potential.
Tullis Health Investors
Tullis Health Investors is a private equity firm specializing in high-growth, commercial-stage healthcare companies. Their investment indicates confidence in BioBDx's ability to scale and impact the healthcare market.
What's next for BioBDx?
The recent major strategic investment signals a pivotal growth phase for BioBDx. This capital injection is expected to accelerate the company's product development pipeline and market penetration for its ADHD diagnostic system. Future endeavors will likely involve scaling manufacturing capabilities, expanding clinical validation studies, and forging strategic partnerships to broaden access to its innovative diagnostic solutions. The company's trajectory suggests a strong focus on solidifying its market position in the behavioral health diagnostics sector.
See full BioBDx company page
